BioAtla faces Nasdaq delisting after listing council affirms suspension decision - BCAB News | RalliesBioAtla faces Nasdaq delisting after listing council affirms suspension decision
B
BCAB• Nasdaq listing council affirms delisting decision
- Nasdaq Listing Council affirmed a decision to delist BioAtla’s common stock from Nasdaq.
- Delisting stems from non-compliance with the $1 minimum bid price rule and failure to meet the $2.5 million stockholders’ equity standard.
- Trading is set to be suspended at the open on Aug. 31, 2026 unless the Nasdaq Board elects to review.
- A Form 25-NSE is expected to be filed with the SEC to remove the shares from Nasdaq listing and registration.
- Shares are expected to become eligible for OTC Markets quotation under symbol BCAB, risking lower liquidity and price pressure.
•
